title: Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study.
abstract: Nine patients with recurrent or refractory epithelial ovarian carcinoma following previous chemotherapy were treated with high-dose carboplatin (300 mg/m2) and ifosfamide according to a dose escalation schedule (1.50, 1.75, 2.00 g/m2), each given intravenously daily for 5 days with autologous bone marrow support. Eight of the nine patients were evaluable for response. Five achieved complete response (CR), all of whom relapsed at 4, 5, 6, 8, and 23 months following treatment. Two partial responses persisted for 6 months, and one patient with stable disease progressed after 2 months and has since died of disease. The median duration of remission was 6 months. The treatment was well tolerated across the doses of ifosfamide with the exception of one treatment-related death which was due to acute renal failure and central nervous system toxicity from ifosfamide. It appears that the use of high-dose chemotherapy with autologous bone marrow support in the treatment of ovarian cancer produced a high rate of response of short duration in this small group of heavily pretreated women.
authors.affiliation: Indiana University/Indiana Regional Cancer Center, Bone Marrow Transplant Unit, Indianapolis.
authors.forename: E R
authors.initials: ER
authors.lastname: Broun
authors.forename: J L
authors.initials: JL
authors.lastname: Belinson
authors.forename: J S
authors.initials: JS
authors.lastname: Berek
authors.forename: D
authors.initials: D
authors.lastname: McIntosh
authors.forename: D
authors.initials: D
authors.lastname: Hurd
authors.forename: H
authors.initials: H
authors.lastname: Ball
authors.forename: S
authors.initials: S
authors.lastname: Williams
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000628:therapy*; D010865:Pilot Projects; D012008:Recurrence; D016879:Salvage Therapy; D014182:Transplantation, Autologous
chemical_list: D016190:Carboplatin; D007069:Ifosfamide